Oral Androgen Receptor Pathway Agents are Changing PCa+ Treatment

Oral AR Pathway Agents are Changing Prostate Cancer Treatment

New theories for castration-resistant prostate cancer have led to the development of new oral androgen receptor pathway agents. In this presentation, Leonard Gomella, MD focuses on two of these agents – abiraterone acetate and enzalutamide. He presents recent data from the registration trials of each agent.

Leonard G. Gomella, MD, FACS
Thomas Jefferson University Hospital

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe